Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study.

Saji S, Yamashita T, Tsurutani J, Sagara Y, Shigematsu H, Takano T, Takahashi M, Araki K, Tamura N, Tsuneizumi M, Morimoto T, Yanai S, Kato A, Yamaguchi M, Kubo S, Hasegawa Y, Tokunaga E, Hasegawa H, Osaka S, Morita S, Sakai K, Masuda N

Open source

DOI: 10.1016/j.esmoop.2026.108325
Published: 2026 Aug
Container: ESMO open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmoop.2026.108325,
  title = {Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study.},
  author = {Saji S and Yamashita T and Tsurutani J and Sagara Y and Shigematsu H and Takano T and Takahashi M and Araki K and Tamura N and Tsuneizumi M and Morimoto T and Yanai S and Kato A and Yamaguchi M and Kubo S and Hasegawa Y and Tokunaga E and Hasegawa H and Osaka S and Morita S and Sakai K and Masuda N},
  year = {2026},
  journal = {ESMO open},
  doi = {10.1016/j.esmoop.2026.108325},
  url = {https://doi.org/10.1016/j.esmoop.2026.108325}
}

RIS

TY  - JOUR
TI  - Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study.
AU  - Saji S
AU  - Yamashita T
AU  - Tsurutani J
AU  - Sagara Y
AU  - Shigematsu H
AU  - Takano T
AU  - Takahashi M
AU  - Araki K
AU  - Tamura N
AU  - Tsuneizumi M
AU  - Morimoto T
AU  - Yanai S
AU  - Kato A
AU  - Yamaguchi M
AU  - Kubo S
AU  - Hasegawa Y
AU  - Tokunaga E
AU  - Hasegawa H
AU  - Osaka S
AU  - Morita S
AU  - Sakai K
AU  - Masuda N
PY  - 2026
JO  - ESMO open
DO  - 10.1016/j.esmoop.2026.108325
UR  - https://doi.org/10.1016/j.esmoop.2026.108325
ER  -

APA

S, S., T, Y., J, T., Y, S., H, S., T, T., M, T., K, A., N, T., M, T., T, M., S, Y., A, K., M, Y., S, K., Y, H., E, T., H, H., S, O., S, M., K, S., & N, M. (2026). Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study.. ESMO open. https://doi.org/10.1016/j.esmoop.2026.108325

Source records

pubmed · retrieved 2026-09-25T16:47:17.865Z
europe-pmc · retrieved 2026-09-25T16:47:17.888Z